https://www.selleckchem.com/pr....oducts/talabostat.ht
Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed doses, which raises concerns of its effectiveness on larger patients. Data from randomized trials are limited on the safety and efficacy of DOACs in morbidly obese individuals with atrial fibrillation (AF). We analyzed a cohort of obese (≥ 120kg) and morbidly obese (BMI 40kg/m ) patients from the Veterans Health Administration system with AF who initiated apixaban, rivaroxaban, dabigatran, or warfarin between years 2012 and 2018. We used inverse probabi
Beğen
Yorum Yap
Paylaş
